RICHMOND, British Columbia, July 29, 2010 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX) today announced that the International Society of Oncology and Biomarkers Congress Scientific Committee has accepted BioCurex’s presentation on the RECAF blood test potential to monitor cancer recurrence and treatment. The meeting will be held Sept. 3-8, 2010 in Munich, Germany and is broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics.
